Sickle Cell Disease Treatment Market Size, Share & COVID-19 Impact Analysis, By Treatment Modality [Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy {Hydroxyurea, and Branded Products (Endari, Adakveo, Oxbryta, Zynteglo, PYRUKYND (Mitapivat), CTX001, Inclacumab, MGTA-145, Vamifeport (VIT-2763), ALXN1820, FT-4202, and GBT021601)}], By End-user [Hospitals, Specialty Clinics, and Others], and Regional Forecast, 2023-2030
Report Id | License Type | Price |
---|---|---|
FBI101009 | $ 4850 | |
Total | $ 4850 |